An AJMC report says an FDA advisory panel voted in July 2026 to recommend six previously restricted peptides for legal compounding, despite unanimous opposition from the agency's own staff scientists. Those scientists cited an absence of human clinical data for four of the seven peptides nominated.

Compounding is not approval. It means a licensed pharmacy may prepare a product from bulk ingredients, which is how compounds like BPC-157 and ipamorelin, both removed from the FDA's restrictive Category 2 list in April 2026, reach patients without ever passing a drug review.

Why the vote matters

The recommendation did not settle the argument so much as publish it. Rachel Strauss, a pharmacy benefit consultant interviewed by AJMC, framed the question as whether patients get these products through legitimate pharmacies and physicians or through the gray market that already exists.

Angela Fitch, MD, past president of the Obesity Medicine Association, was blunter about the committee itself, telling AJMC that many members have conflicts of interest tied to selling these products in their working lives. That is a striking thing for a past society president to say on the record about a federal advisory panel.

What is actually in the vial

The evidence base is thinner than the vote implies. Catherine Varney, DO, of UVA Health cited a scoping review in the American Journal of Sports Medicine finding 67% of peptide publications were preclinical, mostly in rats, and noted that only about 5% of animal-tested interventions ever reach regulatory approval.

Product quality is the sharper problem. Varney pointed to systematic analyses of gray-market peptides containing only 5% to 75% of the labeled amount, alongside Class 1 impurities including arsenic. Asked who verifies any of this before it reaches a patient, she said: "Essentially no one that we know of."

A patchwork, not a policy

Oversight falls largely to state pharmacy boards, where adverse-event reporting is not mandatory and enforcement capacity varies. Connecticut, Alabama, New York, California, Massachusetts and Louisiana have moved to restrict peptide compounding; Texas, Florida, Nevada and Arizona remain permissive.

Bottom line

Meanwhile the FDA has proposed permanently closing the compounding pathway for GLP-1 drugs after more than 455 adverse event reports tied to compounded semaglutide and more than 320 tied to compounded tirzepatide. No similar move has been proposed for peptides resting on a thinner evidence base, and that asymmetry is the story.